Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026)

Nuvalent (NUVL) reported Cash from Investing Activities of -$19.4 million for Q1 2026, down 176.38% on a YoY basis from $25.4 million in Q1 2025, and up 93.09% quarter-over-quarter from -$280.9 million in Q4 2025.

Nuvalent (NUVL) Cash from Investing Activities (2021 - 2026) Analysis & Trends

Nuvalent has reported Cash from Investing Activities for 6 years, with the latest figure at -$19.4 million in Q1 2026.

  • For the quarter ending Q1 2026, Cash from Investing Activities fell 176.38% year-over-year to -$19.4 million; the trailing twelve-month figure through Mar 2026 stood at -$168.9 million (up 50.51% YoY), and the FY2025 full-year result was -$124.1 million, up 78.37% from the prior year.
  • Cash from Investing Activities for Q1 2026 stood at -$19.4 million, up from -$280.9 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $77.5 million in Q2 2025, with the low at -$280.9 million in Q4 2025.
  • Historically, Cash from Investing Activities has averaged -$51.2 million across 5 years, with a median of $1.6 million in 2023.
  • Annual changes were most pronounced in 2023 — Cash from Investing Activities sank 1074.65% — and 2024, when it soared 916.81%.
  • Nuvalent's Cash from Investing Activities stood at -$65.4 million in 2022, then gained by 13.98% to -$56.3 million in 2023, then slumped by 202.24% to -$170.0 million in 2024, then plunged by 65.22% to -$280.9 million in 2025, then jumped by 93.09% to -$19.4 million in 2026.
  • The last three Cash from Investing Activities figures came in at -$19.4 million (Q1 2026), -$280.9 million (Q4 2025), and $54.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -2.89 Mn
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 638.50 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn -431.90 Mn
9 Abivax 91.71 Bn 91.71 Bn - 579,519.10
10 Nuvalent 9.70 Bn 9.70 Bn - -19.41 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -19.41 Mn
Mar 31, 2026 -19.41 Mn
Dec 31, 2025 -280.94 Mn
Dec 31, 2025 -280.94 Mn
Sep 30, 2025 53.97 Mn
Sep 30, 2025 53.97 Mn
Jun 30, 2025 77.48 Mn
Jun 30, 2025 77.48 Mn
Mar 31, 2025 25.42 Mn
Mar 31, 2025 25.42 Mn
Dec 31, 2024 -170.05 Mn
Dec 31, 2024 -170.05 Mn
Sep 30, 2024 -212.91 Mn
Sep 30, 2024 -212.91 Mn
Jun 30, 2024 16.21 Mn
Jun 30, 2024 16.21 Mn
Mar 31, 2024 -206.77 Mn
Mar 31, 2024 -206.77 Mn
Dec 31, 2023 -56.26 Mn
Dec 31, 2023 -56.26 Mn